Back to discover
Disease

Diabetes mellitus, transient neonatal, 3

Late-stage therapeutic development
Also known as KCNJ11 transient neonatal diabetes mellitus (disease), diabetes mellitus, transient neonatal 3, diabetes mellitus, transient neonatal, type 3, transient neonatal diabetes mellitus (disease) caused by mutation in KCNJ11+2 more

KCNJ11 transient neonatal diabetes mellitus (disease), diabetes mellitus, transient neonatal 3, diabetes mellitus, transient neonatal, type 3, transient neonatal diabetes mellitus (disease) caused by mutation in KCNJ11, Tndm3, diabetes mellitus, type II, autosomal dominant.

24
Clinical trials
12
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones13View all 13
Results posted 1
Results expected 5
Other updates 5
+5 more in the activity timeline below
Activity timeline13

Clinical trials

15 sponsors · 3 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR Study

Phase 4 · Active, not recruiting · University of Texas Southwestern Medical Center

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

Phase 4 · Active, not recruiting · Edward Wood, MD

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

Phase 2/3 · Active, not recruiting · EyeBiotech Ltd.

Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Phase 4 · Active, not recruiting · MaryAnn Banerji

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 · Active, not recruiting · Eli Lilly and Company

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes

Phase 3 · Active, not recruiting · Novo Nordisk A/S
Recently completed

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Phase 3 · Completed · Tanabe Pharma Corporation

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Phase 3 · Completed · Alimera Sciences

Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study

Phase 4 · Completed · Korea University Anam Hospital

A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control

Phase 3 · Completed · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes

Phase 4 · Completed · Novartis Pharmaceuticals

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

KCNJ110.80AFMID0.07SUV39H20.06NAGK0.06GIMAP60.06CCDC510.06BIVM0.06DNAJC300.06PLA2G2E0.06CLDND20.06THAP120.05MED110.05

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

ATP-sensitive inward rectifier potassium channel 11via KCNJ110.80

Reference

Authoritative identity, definition & identifiers.

Synonyms

KCNJ11 transient neonatal diabetes mellitus (disease), diabetes mellitus, transient neonatal 3, diabetes mellitus, transient neonatal, type 3, transient neonatal diabetes mellitus (disease) caused by mutation in KCNJ11, Tndm3, diabetes mellitus, type II, autosomal dominant

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.